Parabilis Medicines
@parabilismed.com
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact.
Parabilis Medicines's Company Logos
Parabilis Medicines's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#F45B39
Flamingo
244, 91, 57
11, 89, 59
0, 63, 77, 4
#FFCC98
Peach Orange
255, 204, 152
30, 100, 80
0, 20, 40, 0
#272F33
Outer Space
39, 47, 51
200, 13, 18
24, 8, 0, 80
About Parabilis Medicines
Parabilis Medicines is a pioneering biopharmaceutical company dedicated to transforming the landscape of disease treatment through innovative research and development. With a focus on ultra-tunable peptide therapeutics, Parabilis Medicines aims to deliver extraordinary outcomes for patients facing severe diseases, including cancer. Chief Executive Officer, Mathai Mammen, M.D., Ph.D., emphasizes that the company's mission is not about incremental improvements but about creating life-changing medicines that can have a profound impact on patient lives.
At the core of Parabilis Medicines is its proprietary Helicon™ peptide platform, which enables the development of novel therapeutic options that address unmet medical needs. The company is uniquely positioned to explore solutions to problems previously deemed unsolvable, showcasing a commitment to groundbreaking scientific advancement. Parabilis Medicines, previously known as FogPharma, epitomizes innovation in medicine, continuously striving to redefine treatment possibilities and improve the quality of life for countless individuals. With a robust pipeline of programs, they are at the forefront of creating extraordinary therapies that make a real difference.
Related Brands
Tags
Clinical-stage biopharmaceutical company
Stabilized cell-penetrant peptide therapeutics
Helicon discovery platform
Antibody-drug conjugate–style peptide conjugates
